The regimen under investigation, abbreviated AN + AD, combines brentuximab vedotin and the immune-checkpoint inhibitor nivolumab with two conventional chemotherapy agents, doxorubicin and dacarbazine. Notably absent is bleomycin, the older drug long included in standard front-line Hodgkin lymphoma therapy but increasingly viewed as a liability because of its association with lung toxicity. By substituting targeted agents for bleomycin and, in this study, limiting treatment to just four cycles, the investigators set out to test whether precision medicine could allow patients with favorable disease biology to receive less chemotherapy without sacrificing the exceptional cure rates that define this cancer.

The patient population was carefully defined. The trial enrolled people with nonbulky, early-stage classical Hodgkin lymphoma, meaning their disease was limited to lymph node regions above or below the diaphragm without large tumor masses, a feature that generally predicts a more favorable course. At the time of the analysis, 154 patients had received at least one dose of the four-drug combination, and an overwhelming 98 percent had completed all four planned cycles of treatment. That near-complete adherence to the treatment schedule is itself a meaningful signal in oncology trials, suggesting the regimen was tolerable enough for patients to stay on course.

The efficacy numbers were remarkable across the board. At the end of treatment, the objective response rate, which counts patients whose tumors shrank at least partially, stood at 96 percent. The complete response rate, meaning no detectable disease remained, was 92 percent overall. When the investigators broke the results down by risk group, the picture held steady: patients in the favorable-risk subgroup achieved a complete response rate of 95 percent, while those in the unfavorable subgroup, who typically carry a worse prognosis, still reached 91 percent. The near-identical outcomes across risk categories suggest the addition of the targeted agents may be compressing the historical gap between patient groups that standard chemotherapy has struggled to close.

Durability, the question that matters most in a disease where most patients are young and expected to live decades, also looked strong. Among patients who achieved a complete response, 96 percent maintained it for at least two years. At a median follow-up of 27.9 months, the estimated two-year progression-free survival rate was 97 percent, meaning almost no patients had seen their lymphoma return or worsen within that window. For a disease that strikes disproportionately at young adults, a regimen that combines such high cure indicators with reduced chemotherapy exposure carries implications that extend far beyond the trial population, since late toxicities of Hodgkin lymphoma treatment, including cardiovascular damage and secondary cancers, are a major long-term concern for survivors.

The safety profile, while not benign, was consistent with what is known about the individual components. Any-grade treatment-related side effects occurred in 97 percent of patients, a figure that sounds alarming until placed in context: nearly all cancer regimens produce some side effects in nearly all patients, and the vast majority of these events were low grade. More telling is the grade 3 or higher rate, which captures the serious toxicities that threaten treatment delivery, and here the figure was 34 percent. Strikingly, no cases of febrile neutropenia, the dangerous fever-plus-low-white-blood-count emergency that often drives hospitalization during chemotherapy, were reported at all, a result that speaks to both the tolerability of the regimen and the feasibility of delivering it in community as well as academic settings.

Because nivolumab works by releasing a molecular brake on T cells, the immune-mediated adverse events characteristic of checkpoint inhibitors were a specific focus of monitoring. Treatment-emergent immune-mediated adverse events of any grade occurred in 22 percent of patients. These events, which can include inflammation of the thyroid, skin, lungs, or other organs, arise from the same immune reactivation that makes checkpoint inhibitors effective against cancer, and they are generally manageable with immunosuppressive medication when recognized early. The 22 percent rate provides clinicians with a concrete expectation of how often such monitoring and management will be needed if the regimen moves into routine practice.

The mechanistic logic behind the combination is one of the reasons the results have generated such attention. Brentuximab vedotin is an antibody-drug conjugate that homes in on CD30, a surface molecule displayed prominently on the malignant Reed-Sternberg cells of Hodgkin lymphoma, and delivers a payload of monomethyl auristatin E that disrupts cell division. Nivolumab blocks the PD-1 pathway, which Hodgkin lymphoma cells exploit to hide from immune attack, in part through genetic alterations that drive overexpression of the PD-L1 ligand. Doxorubicin and dacarbazine provide conventional cytotoxic killing. Preclinical and clinical evidence has suggested that chemotherapy and antibody-drug conjugates can each potentiate antitumor immunity, creating a rationale for pairing them with checkpoint blockade, and the SGN35-027 results lend clinical weight to that hypothesis.

The study was a broad international collaboration, with investigators spanning major cancer centers and community oncology networks across the United States and sites in Europe and Australia. The author group was led by Jeremy S. Abramson of Massachusetts General Hospital and included figures such as David J. Straus of Memorial Sloan Kettering Cancer Center, Nancy L. Bartlett of Washington University School of Medicine, Ryan C. Lynch of Fred Hutchinson Cancer Center, and Wojciech Jurczak of the Maria Sklodowska-Curie National Research Institute of Oncology in Krakow, alongside colleagues from Spain, Italy, Australia, and a range of US centers. Data from the study were previously presented at the 2024 American Society of Hematology Annual Meeting and Exposition in San Diego, and the work received funding support from Seagen, Inc., which was acquired by Pfizer in December 2023, together with Takeda Development Center Americas and Bristol-Myers Squibb, with additional support from a Memorial Sloan Kettering Cancer Center core grant.

The authors and the journal are careful to frame the findings appropriately. The published summary emphasizes that it reports the results of a single study, that results may differ from those of other studies, and that health professionals should make treatment decisions based on all available evidence rather than on one trial. It also notes explicitly that the combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine is not approved for the treatment of people with early-stage classical Hodgkin lymphoma. Those caveats matter, but they do little to dull the significance of the numbers. Classical Hodgkin lymphoma is already one of oncology’s success stories, yet each incremental gain in survival has traditionally been purchased with more intensive therapy and more late effects. A four-cycle, bleomycin-free regimen that pairs two rational targeted agents with limited chemotherapy and delivers 97 percent two-year progression-free survival points toward a future in which curing this cancer requires less treatment, not more, and in which the young patients who make up the bulk of the Hodgkin lymphoma population can look forward not just to survival but to decades of healthier life afterward.

Subject of Research: Combination therapy with brentuximab vedotin, nivolumab, and chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma

Article Title: Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Article References: Abramson, J. S., Straus, D. J., Bartlett, N. L., Burke, J. M., Lynch, R. C., Domenech, E. D., Hess, B., Schuster, S. R., Linhares, Y., Gandhi, M., Shah, H. R., Jurczak, W., Re, A., Hahn, U., Prince, H. M., Guo, W., Davis, G., Ho, L., Fanale, M., … Lee, H. J. (2026). Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma. Advances in Therapy. https://doi.org/10.1007/s12325-026-03723-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03723-z

Keywords: brentuximab vedotin, nivolumab, classical Hodgkin lymphoma, chemotherapy, antibody-drug conjugate, immune checkpoint inhibitor, phase 2 trial, progression-free survival, complete response, doxorubicin, dacarbazine, hematologic oncology

The cancer in question is anaplastic large cell lymphoma, or ALCL, a rare T-cell non-Hodgkin lymphoma that exists in several biologically distinct forms. Systemic ALCL is classified as ALK-positive or ALK-negative depending on whether the tumor carries the ALK fusion oncogene, while separate entities include breast implant-associated ALCL and primary cutaneous ALCL. For most adults with systemic disease, first-line therapy consists of anthracycline-based chemotherapy, with the antibody-drug conjugate brentuximab vedotin combined with cyclophosphamide, doxorubicin and prednisone, known as BV-CHP, now the preferred regimen for CD30-positive cases. When the disease returns or stops responding, options include brentuximab vedotin alone, autologous or allogeneic stem cell transplantation, and ALK inhibitors for relapsed ALK-positive disease. Brentuximab vedotin achieves complete remission in roughly 60 percent of relapsed or refractory patients, but for those who fail to reach remission, median overall survival is only 9.5 months, a statistic that underscores how desperately new strategies are needed.

The patient’s journey began in May 2017, when she presented at age 75 with chronic diarrhea and weight loss. Initial workups for infections, celiac disease and inflammatory bowel disease, along with colonoscopy, all came back negative. Her symptoms worsened, and in July 2017 she developed a small-bowel obstruction requiring surgical resection. Histopathology of the resected tissue delivered the diagnosis: ALK-negative ALCL at stage IVB, meaning the disease had already spread widely. Eight cycles of the standard CHOP chemotherapy regimen produced a complete response, but the lymphoma returned just three months after treatment ended in February 2018. What followed was a years-long cycle of remission and relapse that would exhaust nearly every established option.

Second-line brentuximab vedotin at 1.8 milligrams per kilogram of body weight brought another complete response after eight cycles. Six months after the drug was stopped, the disease relapsed again in February 2019, prompting re-initiation of brentuximab vedotin for an additional 33 cycles. Once more the patient achieved a complete metabolic response, confirmed by PET/CT imaging, and treatment was discontinued in February 2021. Fifteen months later, in May 2022, a third relapse occurred. Because she had developed grade 1 to 2 peripheral neuropathy, a known cumulative toxicity of the antibody-drug conjugate, brentuximab vedotin was withheld. The team instead chose lenalidomide, an immunomodulatory agent given at 15 milligrams daily for 21 days of each 28-day cycle, which stabilized the disease temporarily. After seven cycles, the lymphoma progressed in November 2022.

A final brentuximab vedotin re-challenge, six cycles from April to August 2023, failed entirely. At that point, with few options remaining, the clinicians turned to comprehensive genomic profiling of circulating tumor DNA using the FoundationOne Liquid assay. The September 2023 analysis revealed a tumor mutational burden of 23 mutations per megabase, a figure well above the thresholds generally considered high. Tumor mutational burden and microsatellite instability have emerged as predictive biomarkers for immune checkpoint blockade in several solid tumors, where tumors carrying many mutations produce more abnormal proteins that the immune system can recognize. On that tissue-agnostic rationale, and with no standard alternatives left, the team began nivolumab, initially at 240 milligrams every two weeks and later modified to 480 milligrams every four weeks.

The response was striking. Clinical improvement appeared within two months, and at the first formal response assessment in March 2024, roughly six months after starting therapy, imaging showed a complete metabolic remission. The treatment was not without consequences: in April 2024 the patient developed grade 2 immune-related thyroiditis, an inflammation of the thyroid gland typical of checkpoint inhibitor toxicity, which was managed with thyroid hormone replacement and did not require stopping nivolumab. She continued the drug until November 2025, completing 25 months of treatment. In December 2025 she suffered a myocardial infarction requiring percutaneous coronary intervention with stent implantation, but given her sustained remission, no further nivolumab was administered. At her most recent follow-up in July 2026, eight months after the last dose, she remains in complete metabolic remission with no detectable tumor-associated alterations on repeat liquid biopsy, and reports good overall condition with an ECOG performance status of 1.

To understand how unusual this outcome is, the authors systematically reviewed the literature and found only three previously published adult cases of relapsed or refractory ALCL treated with immune checkpoint inhibitors. Chan and colleagues described a 35-year-old woman with ALK-negative disease who, after multiple chemotherapy failures, autologous transplantation and a relapse three months after allogeneic transplantation, achieved complete response on pembrolizumab within about 70 days, with elevated transaminases as the only side effect. Hebart and colleagues reported a 19-year-old man with ALK-positive disease who had relapsed despite chemotherapy, brentuximab vedotin, the ALK inhibitor crizotinib and autologous transplantation; nivolumab produced complete response within one month, with pneumonitis after 12 cycles treated successfully with corticosteroids. Barta and colleagues included one ALK-negative ALCL patient in a phase 2 trial of PD-1 or PD-L1 inhibition in relapsed T-cell lymphomas; although the trial was halted early for limited efficacy overall, that single patient remained in complete remission for 18 months at publication. A pediatric case reported by Rigaud and colleagues, a 17-year-old with ALK-positive disease treated third-line with nivolumab, adds further support, with rapid response and remission maintained 18 months after initiation.

Taken together, all four adult patients, including the present case, achieved complete remission and remained progression-free across reported observation periods of 4, 9, 18 and 33 months. Where safety data were available, adverse events were manageable and consistent with the established immune-related toxicity profile of PD-1 inhibitors, though the authors caution that patients treated after allogeneic stem cell transplantation face an elevated risk of graft-versus-host disease. The authors are equally clear about the limits of this evidence. Case reports carry strong publication bias, because unsuccessful treatments are far less likely to be published, making it impossible to estimate the true response rate of checkpoint blockade in ALCL. There is currently no validated evidence that tumor mutational burden predicts benefit from immunotherapy in ALCL or other T-cell lymphomas, so the treatment selection in this case was extrapolated from tissue-agnostic approvals in TMB-high solid tumors and should be regarded as hypothesis-generating rather than evidence-based.

Two additional findings may shape future research. Retrospective immunohistochemical analysis of the patient’s original 2017 tumor sample, performed during preparation of the manuscript, showed PD-L1 expression in 95 percent of tumor cells, though whether this contributed to the favorable response remains speculative. The biology of PD-L1 expression also differs between ALCL subtypes: in ALK-positive disease, PD-L1 is driven by oncogenic signaling downstream of ALK with constitutive STAT3 activation playing a central role, whereas ALK-negative disease lacks this driver and PD-L1 may be regulated through alternative STAT3- and MYC-dependent transcriptional programs, a distinction the authors argue demands separate evaluation of the subtypes in future studies. Serial circulating tumor DNA assessment, which tracked this patient’s response and confirmed molecular remission, may also warrant investigation as a monitoring tool in ALCL. The authors conclude that immune checkpoint inhibition should not yet be considered standard treatment for relapsed or refractory ALCL, but may be considered individually, preferably within a clinical trial or structured translational program, for patients who have exhausted established alternatives, and that prospective studies are needed to define efficacy, safety, optimal treatment duration and biomarker-guided patient selection, including rational combinations with brentuximab vedotin whose mechanisms of action may prove complementary.

Subject of Research: Immune checkpoint inhibitor therapy guided by genomic profiling in relapsed or refractory anaplastic large cell lymphoma

Article Title: Immune Checkpoint Inhibitors in Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL): A Case Report and Review of the Literature

Article References: Klenner, C., & Singer, J. (2026). Immune Checkpoint Inhibitors in Relapsed/Refractory Anaplastic Large Cell Lymphoma ( ALCL ): A Case Report and Review of the Literature. Cancer Reports, 9(9), Article e70684. https://doi.org/10.1002/cnr2.70684

Image Credits: AI Generated

DOI: 10.1002/cnr2.70684

Keywords: anaplastic large cell lymphoma, immune checkpoint inhibitors, nivolumab, PD-1 blockade, tumor mutational burden, liquid biopsy, circulating tumor DNA, brentuximab vedotin, PD-L1 expression, T-cell lymphoma, precision oncology, case report

The research, conducted as a single-center, nonrandomized controlled phase II study, enrolled sixty-one children with newly diagnosed classic Hodgkin lymphoma between October 2022 and January 2026. Thirteen of the participants were classified as intermediate risk, while forty-eight fell into the high-risk category. Rather than applying a one-size-fits-all protocol, the investigators used risk stratification to tailor the intensity of chemoimmunotherapy to each child’s disease profile, an approach designed to maximize cure while minimizing unnecessary exposure to toxic agents.

At the heart of the regimen sits brentuximab vedotin, an antibody-drug conjugate that homes in on CD30, a surface marker abundantly expressed by the malignant Reed-Sternberg cells that define classic Hodgkin lymphoma. The drug links a monoclonal antibody to monomethyl auristatin E, a potent cell-killing payload, delivering the toxin selectively to tumor cells while sparing healthy tissue. In this study, brentuximab vedotin was combined with rituximab, an anti-CD20 antibody, and woven into chemotherapy backbones that included agents such as doxorubicin, vinblastine, and dacarbazine for high-risk patients, with risk-adapted modifications incorporating drugs like ifosfamide and vinorelbine where disease response demanded them.

The results, reported in Annals of Hematology, are striking. Fifty-four of the sixty-one children, or 88.5 percent, achieved a complete metabolic response by the end of chemoimmunotherapy, meaning that advanced imaging could detect no residual metabolically active disease. Even more telling, 83.6 percent of patients qualified as rapid early responders, showing swift clearance of lymphoma after initial treatment cycles. Because early response has traditionally been the trigger for adding involved-field radiotherapy, the high proportion of rapid responders allowed the investigators to withhold radiation in most cases: 86.9 percent of the children completed treatment without any involved-field radiotherapy at all.

Survival figures underscore the effectiveness of the strategy. With a median follow-up of twenty-four months, ranging from nine to thirty-five months, event-free survival for the entire cohort reached 96.7 percent, and overall survival stood at a remarkable 100 percent. Not a single child died, and none were lost to follow-up, an unusually complete dataset for any oncology study. For the small number of patients who did relapse, retreatment with conventional chemotherapy remained effective, suggesting that the antibody-based frontline approach did not compromise salvage options.

Toxicity data were equally encouraging. Only 8.2 percent of children experienced grade 1 to 2 myelosuppression, the bone marrow suppression that commonly complicates chemotherapy. Two patients, or 3.3 percent, developed mild grade 2 peripheral neuropathy, a known and generally reversible side effect of the vedotin payload class, and one child, 1.6 percent, had a grade 2 allergic reaction to brentuximab vedotin itself. No severe toxicities were highlighted, and the overall safety profile appeared manageable in this pediatric population, a critical consideration given that children’s developing tissues are especially vulnerable to the cumulative harms of cytotoxic therapy.

Beyond immediate safety, the researchers probed a question that matters enormously for children who must live decades beyond their cure: what happens to the immune system? Among the fifty-two patients followed for twelve months or longer, laboratory assessments showed an immunoglobulin G level of 19.2 plus or minus 0.9 grams per liter and an absolute total B-cell count of 190.9 plus or minus 8.3 cells per microliter, both comfortably within the normal range. This finding is notable because rituximab depletes B cells and intensive chemotherapy can impair humoral immunity, leaving survivors susceptible to infections. The preserved immune profiles suggest that the risk-adapted design successfully limited immunological damage, though longer observation will be needed to confirm durability.

The study’s design carries both strengths and caveats. As a single-center, nonrandomized controlled trial, it lacked the randomization that guards against selection bias, and all patients were treated at one institution in China, raising questions about generalizability to other populations and health systems. The authors themselves are careful on this point, concluding that the regimen demonstrates safety in Chinese pediatric patients with newly diagnosed classic Hodgkin lymphoma while emphasizing that larger cohort studies are needed to validate these preliminary findings. Still, the prospective design, complete follow-up, and detailed risk stratification lend considerable weight to the results.

The broader significance lies in what the study represents for the field. Pediatric Hodgkin lymphoma treatment has been steadily migrating toward response-adapted and risk-adapted paradigms, in which the intensity of therapy is dictated by how the disease behaves rather than by its stage alone. By adding a CD30-targeted antibody-drug conjugate to that framework, the Beijing team provides some of the strongest pediatric evidence yet that targeted immunotherapy can substitute for radiation in most children, potentially sparing them the secondary cancers, cardiovascular disease, and growth disturbances that radiation can seed years later. The trial was registered at ClinicalTrials.gov under identifier NCT06201507 and approved by the Institutional Review Board of Beijing Children’s Hospital, with all families providing informed consent under the principles of the Declaration of Helsinki.

For now, the message for families and clinicians is one of cautious optimism. Nearly nine in ten children achieved complete metabolic response, nearly nine in ten avoided radiation, every child survived, and immune function remained intact at one year. If larger, multicenter studies confirm these findings, brentuximab vedotin-based risk-adapted chemoimmunotherapy could become a new benchmark for treating childhood Hodgkin lymphoma, one that cures the cancer without mortgaging the child’s long-term health to do it.

Subject of Research: Brentuximab vedotin combined with risk-adapted chemoimmunotherapy for pediatric classic Hodgkin lymphoma

Article Title: Brentuximab vedotin combined with risk-adapted chemoimmunotherapy for Hodgkin’s lymphoma in Chinese children: a single-center, nonrandomized controlled study

Article References: Brentuximab vedotin combined with risk-adapted chemoimmunotherapy for Hodgkin’s lymphoma in Chinese children: a single-center, nonrandomized controlled study. (n.d.). https://doi.org/10.1007/s00277-026-07273-w

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07273-w

Keywords: Hodgkin lymphoma, brentuximab vedotin, pediatric oncology, chemoimmunotherapy, risk-adapted chemotherapy, rituximab, antibody-drug conjugate, involved-field radiotherapy, event-free survival, cancer immunotherapy, children's cancer, Annals of Hematology